Baker McKenzie advised 4SC AG ("4SC", www.4sc.com) on its capital increase by way of a rights offering and an international private placement of a total of 4,676,703 new shares. The new shares were admitted to trading on 4 July 2019 on the Frankfurt Stock Exchange, the transaction closed today.
MainFirst Bank AG, Frankfurt am Main ("MainFirst") acted as underwriter and as placement agent for the new shares.
Baker McKenzie acted as German and international counsel for 4SC on all legal aspects of the transaction, working with an integrated team from its Equity Capital Markets, Corporate and Healthcare Practices.
4SC is a clinical-stage biopharmaceutical company which develops small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.
4SC is headquartered in Planegg-Martinsried near Munich, Germany. The company has 47 employees and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard).
On the Equity Capital Markets side, the team around Christoph Wolf lately advised the banks led by Berenberg on the € 150 million Aluflexpack IPO and a fund held by SINO-CEE as cornerstone investor in the € 278 million capital increase, share admission and share placement of Quingdao Haier Co., Ltd., in Frankfurt.
Baker McKenzie's Corporate team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised MODAG on €12 million Series A Financing, Hitachi Chemical on the acquisition of apceth Biopharma, Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation, Mundipharma on the sale of its Limburg production, CureVac AG on a collaboration with Eli Lilly and Hillhouse Capital as co-investor in the € 50 million Series C cross-over financing of Hookipa Biotech.
Legal Advisor to 4SC AG:
Lead: Dr. Christoph Wolf (Equity Capital Markets, Corporate, Partner, Frankfurt)
Core Team: Capital Markets: Ulrich Weidemann (Counsel, Frankfurt)
Corporate: Berthold A. Hummel (Partner, Munich), Dr. Katja Heuterkes (Counsel, Sydney/Munich)
Healthcare/Pharma: Dr. Thilo Räpple (Partner, Frankfurt), Dr. Martin Altschwager (Senior Associate, Frankfurt)
IP: Dr. Michael Fammler (Partner, Frankfurt), Dr. Markus Hecht (Associate, Frankfurt)
Employment: Dr. Christian Reichel (Partner, Frankfurt), Cornelius Ziegler (Associate, Frankfurt)
Tax: Dr. Thomas Schänzle (Partner, Frankfurt), Amar Hamouche (Tax Director, Luxembourg)